ArticleCancer research2022
Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 14 citations in OpenAlex.
- Cigarette smoke induces FASN-dependent fatty acid metabolic rewiring to drive bladder cancer progression.Cancer letters · 2026Article
- Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2026Article
- Targeting Post-Irradiation Thyroid Dysfunction: Electrospun Scaffolds As A Dual-Action Approach for Antioxidant and Immune Modulation.Advanced healthcare materials · 2026Article
- Advances in artificial metabzymes for macrophage polarization in tumor metabolic immunotherapy.Materials today. Bio · 2026Article
- Tumor-infiltrating natural killer cell profiling for therapeutic stratification in patients with resectable non-small cell lung cancer.bioRxiv : the preprint server for biology · 2026Article
- Research Progress of Multicomponent Co-Loaded Nanomedicine Delivery Systems for Tumor Immunotherapy.International journal of nanomedicine · 2026Review
- NFATC3 enhances osteosarcoma progression by increasing PD-L1 and CXCL2 levels.Medical oncology (Northwood, London, England) · 2025Article
- Traditional Chinese medicine in the prevention and treatment of lung cancer metastasis by regulating tumor-associated macrophages: a narrative review.Translational lung cancer research · 2025Review
- Emerging macrophage-based therapies for cancer: a review of preclinical and clinical advances.Frontiers in immunology · 2025Review
- Blocking M2-Like Macrophage Polarization Using Decoy Oligodeoxynucleotide-Based Gene Therapy Prevents Immune Evasion for Pancreatic Cancer Treatment.Molecular cancer therapeutics · 2024Article
- Unraveling the tumor immune microenvironment of lung adenocarcinoma using single-cell RNA sequencing.Therapeutic advances in medical oncology · 2024Review
- Heterogeneity of the tumor immune microenvironment and clinical interventions.Frontiers of medicine · 2023Review
- Alveolar macrophages in lung cancer: opportunities challenges.Frontiers in immunology · 2023Review
- Tumor-associated macrophages in direct contact with prostate cancer cells promote malignant proliferation and metastasis through NOTCH1 pathway.International journal of biological sciences · 2022Article
- Innate Immune Memory in Macrophages.Newborn (Clarksville, Md.)Article
Corrections and comments
- Commented on by
Authors and funding
18 authors at 5 institutions in 1 country.
Hee-Jin Jang *Systems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-7031-1398
Hyun-Sung Lee *Systems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-8259-046X
Wendong YuDepartment of Pathology/Laboratory Medicine, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Maheshwari RamineniDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, Texas.
Cynthia Y TruongSystems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Daniela RamosSystems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Taylor SplawnSystems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Jong Min ChoiSystems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Sung Yun JungDepartment of Biochemistry and Molecular Biology, Baylor College of Medicine, Houston, Texas.ORCID 0000-0003-1521-7977
Ju-Seog LeeDepartment of Systems Biology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Daniel Y WangDivision of Hemato-Oncology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Joel M SederstromAdvanced Technology Cores, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0001-7398-3480
Massimo PietropaoloDivision of Endocrinology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Farrah KheradmandDivision of Pulmonology, Department of Medicine, Baylor College of Medicine, Houston, Texas.
Christopher I AmosORCID 0000-0002-8540-7023
Thomas M Wheeler
R Taylor Ripley
Bryan M Burt *Systems Onco-Immunology Laboratory, The David J. Sugarbaker Division of Thoracic Surgery, Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas.
Michael E. DeBakey VA Medical Center · USBaylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · USChildren's Cancer Center · USHouston Institute for Clinical Research · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MTumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Michael M Ittmann · 2007 to 2026
$73.9MTranslating Molecular and Clinical Data to Population Lung Cancer Risk AssessmentU19CA203654 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Rayjean J. Hung · 2017 to 2026
$23.7MProteomic determinants of response to checkpoint blockade in malignant pleuralmesotheliomaR37CA248478 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Bryan Michael Burt · 2021 to 2026
$2.9MSingle Cell Spatial Analysis in TissueR50CA243707 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BURKS, JARED KYLE · 2020 to 2024
$1.3MBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kNCI NIH HHS P30 CA016672NCI NIH HHS P30 CA125123NCI NIH HHS R37 CA248478NCI NIH HHS R50 CA243707NCI NIH HHS U19 CA203654NCRR NIH HHS S10 RR024574
Abstract
significanceComprehensive single-cell proteomics analyses of lung adenocarcinoma progression reveal the role of tumor-associated macrophages in resistance to PD-1 blockade therapy. See related commentary by Lee et al., p. 2515.
Indexed as
AdenocarcinomaAdenocarcinoma of LungLung NeoplasmsHumansMacrophagesTumor Microenvironment
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.